Lundbeck's Parkinson's Candidate Shows Early Promise in Phase 1b Trial
Event summary
- Lundbeck's Phase 1b trial for Lu AF28996 in advanced Parkinson's disease showed promising safety and early clinical signals.
- The orally administered D1/D2 receptor agonist will be presented at the AD/PD™ 2026 conference (March 17-21).
- Lundbeck plans to initiate a Phase 2 study for Lu AF28996 in 2026.
- The company also presented data on multiple system atrophy (MSA) and its amlenetug program.
The big picture
Lundbeck's Phase 1b data for Lu AF28996 underscores its focus on advancing treatments for advanced Parkinson's disease, an area with significant unmet needs. The company's broader R&D pipeline in movement disorders, including MSA, highlights its strategic commitment to neuroscience. Success in these programs could solidify Lundbeck's position as a key player in neurodegenerative disease therapies.
What we're watching
- Clinical Progression
- Whether Lu AF28996 can demonstrate sustained efficacy in Phase 2 trials for advanced Parkinson's disease.
- Regulatory Pathway
- The pace at which Lundbeck advances Lu AF28996 through clinical development given the unmet need in Parkinson's.
- Competitive Landscape
- How Lundbeck's MSA program with amlenetug positions it against competitors in the neurodegenerative disease space.
Our editorial coverage: